amogastrin

English Journal

Effect of amogastrin on the release of various prostaglandins into gastric lumen in man.

Saitoh O1, Tei H, Okumura Y, Asada S, Hirata I, Ohshiba S.
Japanese journal of medicine.Jpn J Med.1989 Mar-Apr;28(2):175-9.
The effect of amogastrin on the release of 5 types of prostaglandins (PGs) [PGE2, 6-keto-PGF1 alpha, PGF2 alpha, PGD2, and thromboxan B2 (TXB2)] into the gastric lumen was evaluated in seven healthy volunteers. Gastric juice was obtained under basal and amogastrin-stimulated conditions. The 5 types
PMID 2733241

Gastric protective effects of gastric secretagogues on 0.6N HCl-induced gastric lesions in rats.

Isobe Y1, Hirose-Kijima H, Muramatsu M, Aihara H.
Archives internationales de pharmacodynamie et de thérapie.Arch Int Pharmacodyn Ther.1988 Sep-Oct;295:270-81.
The effects of gastric secretagogues on 0.6N HCl-induced gastric lesions and gastric mucosal prostaglandin E2 (PGE2) contents were investigated in rats. Secretagogues such as histamine (Hist) and amogastrin (Gast) significantly inhibited the formation of gastric lesions induced by 0.6N HCl. The time
PMID 3245741

Antisecretory effect of a PGE2 derivative, enprostil (TA/RS-84135): inhibitory action of amogastrin-stimulated secretion.

Kohli Y1, Katoh T, Suzuki K.
Drugs under experimental and clinical research.Drugs Exp Clin Res.1988;14(11):673-8.
A newly developed prostaglandin E2 derivative, enprostil (TA/RS-84135), was administered to five healthy volunteers in the stomach and duodenum through a teflon tube to examine its effect on amogastrin-stimulated gastric acid secretion. The acid output 1-3 h after administration of enprostil (35 mic
PMID 3149933